` PRQR (ProQR Therapeutics NV) vs S&P 500 Comparison - Alpha Spread

PRQR
vs
S&P 500

Over the past 12 months, PRQR has underperformed S&P 500, delivering a return of -32% compared to the S&P 500's +13% growth.

Stocks Performance
PRQR vs S&P 500

Loading
PRQR
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PRQR vs S&P 500

Performance Gap Between PRQR and GSPC
HIDDEN
Show

Performance By Year
PRQR vs S&P 500

Loading
PRQR
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ProQR Therapeutics NV vs Peers

S&P 500
PRQR
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ProQR Therapeutics NV
Glance View

Market Cap
241.3m USD
Industry
Biotechnology

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

PRQR Intrinsic Value
HIDDEN
Show
Back to Top